retatrutide phase 2 trial dosing schedule Weight Loss Treatment Explained VisualAbstract: Retatrutide reduces body weight

Mechanism of Action: Triple Receptor Agonist Retatrutide is a synthetic peptide that activates three key metabolic receptors: GLP-1 (Glucagon-Like Peptide-1) Enhances insulin secretion, suppresses appetite, delays gastric emptying GIP (Glucose-Dependent Insulinotropic Polypeptide) Boosts insulin response, improves insulin sensitivity, may support lipid metabolism Glucagon Receptor (GCGR) Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat This triple agonist profile delivers synergistic effects on glycemic control, fat loss, and metabolic health, making Retatrutide the most advanced incretin-based peptide in development

Klinic will offer retatrutide prescriptions once the medication is approved, and we will facilitate availability through trusted pharmacy partners

At Vive Ageless Weight Loss Center, under the expert guidance of Rafael Olartecoechea, we understand the complexities of managing chronic conditions like type 2 diabetes and obesity

In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called ileal braking effect (19, 35)